MGN-002

MGN-002 is a preclinical-stage antibody-drug conjugate (ADC) being developed by MetaGen Biologics for the treatment of breast cancer and gastric cancer. The drug is engineered using the company's proprietary 3rdGO ADC engineering platform, which utilizes site-specific conjugation technology to attach a cytotoxic payload to a monoclonal antibody. This platform is designed to create more stable and homogeneous ADCs compared to traditional random conjugation methods, potentially improving the therapeutic index and safety profile of the conjugate. MGN-002 is intended to selectively deliver its cytotoxic payload to tumor cells, thereby inducing cell death while minimizing damage to healthy tissue.